Deucravacitinib is very potent and selective allosteric inhibitor of tyrosine kinase 2 (TYK2). It binds to and is selective for the TYK2 pseudokinase domain (JH2, IC50 = 0.2 nM), with no activity against canonical JH1 domain of TYK2, JAK1,2, or 3.1 It is
* VAT and and shipping costs not included. Errors and price changes excepted